{"created":"2024-12-03T01:53:38.967944+00:00","id":2002036,"links":{},"metadata":{"_buckets":{"deposit":"00dd1478-62cf-4fd5-8006-5a88965cf4ab"},"_deposit":{"created_by":8,"id":"2002036","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2002036"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02002036","sets":["1732778801467:1732778962699:1733190542397"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Sugimoto, Mitsuru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takagi, Tadayuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Suzuki, Rei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Konno, Naoki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Asama, Hiroyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sato, Yuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Irie, Hiroki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okubo, Yoshinori","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakamura, Jun","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takasumi, Mika","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hashimoto, Minami","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kato, Tsunetaka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kobashi, Ryoichiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hikichi, Takuto","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ohira, Hiromasa","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-sa/4.0/"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Peripheral neuropathy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pancreatic cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Oxaliplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nab-paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Antineoplastic Agents","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Duloxetine Hydrochloride","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Oxaliplatin","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Pancreatic Neoplasms","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Peripheral Nervous System Diseases","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Pregabalin","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Randomized Controlled Trials as Topic","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"The Fukushima Society of Medical Science","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0016-2590","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2185-4610","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA0065246X","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"10","bibliographicPageStart":"1","bibliographicVolumeNumber":"68","bibliographic_titles":[{"bibliographic_title":"Fukushima Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.5387/fms.2021-32","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"35197393","subitem_relation_type_select":"PMID"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"2023116777","subitem_relation_type_select":"ICHUSHI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2022-04-15"}],"displaytype":"detail","filename":"FksmJMedSci_68_p1.pdf","filesize":[{"value":"246.2 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2002036/files/FksmJMedSci_68_p1.pdf"},"version_id":"415a2c1d-86c2-4b1a-84b7-5538ddc78007"}]},"item_title":"Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer","item_type_id":"40002","owner":"8","path":["1733190542397"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-04-15"},"publish_date":"2022-04-15","publish_status":"0","recid":"2002036","relation_version_is_last":true,"title":["Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2024-12-03T02:05:02.453138+00:00"}